All News
RA-ILD: Screening risk and genetic susceptibility
RA-ILD remains one of the most serious extra-articular manifestations of RA, contributing substantially to morbidity and mortality. Two abstracts presented at EULAR 2026 add important insights into identifying patients at risk for RA-ILD and understanding the genetic mechanisms that may underpin disease development.
Read Article
Vasculitis Updates: Glucocorticoid use in AAV and GCA
2026 EULAR Press Release
Glucocorticoids are the cornerstone of initial vasculitis treatment, used to rapidly control inflammation and protect vital organs. EULAR has recommendations that cover glucocorticoid use in ANCA associated vasculitides (AAV) and large vessel vasculitis, including giant cell arteritis (GCA).1,2 But the evidence base continues to grow about their use – especially over the long term.
Read Article
New Insights in Gout Clinical Management
https://t.co/Eo63NUhaY2 https://t.co/oHZG1c1LhL
Dr. John Cush RheumNow ( View Tweet)
Getting #RA and IA diagnosed faster: UK RheumACaN program (integrated education + pathway redesign) ↑ clinician confidence 4.4 to 8.6/10. Referral within 3 days: 52% → 70%, with sustained improvement. Education that translates to real outcomes. @RheumNow #EULAR2026 POS0784 https://t.co/1Va9rkLBHM
Jiha Lee JihaRheum ( View Tweet)
💉Do GLP-1 agonists improve DMARD persistence in PsA/axSpA?
TriNetX real-world study (n=3,068): YES!
Better b/tsDMARD persistence and lower stroke & mortality risk
#POS0194 #EULAR2026 @rheumnow
Nelly ZIADE 🍀 Nellziade ( View Tweet)
⏰ The question rheumatologists keep asking: Does early axSpA diagnosis reduce long-term spinal damage?
Answer from the SCQM registry (n=376): Early diagnosis linked to 3.85 fewer mSASSS points long-term, esp. in HLA-B27+ males
#POS0191 #EULAR2026 @RheumNow https://t.co/HM5kvqXMEh
Nelly ZIADE 🍀 Nellziade ( View Tweet)
📋 Do 2025 ASAS-SPARTAN criteria classify fewer real-world axSpA patients?
Data from the RABBIT-SpA registry (n=2,236) confirms:
67% vs 73% with 2009 criteria
Clinical arm rarely fulfilled
#POS0190 #EULAR2026 @RheumNow https://t.co/HYie4w8c6r
Nelly ZIADE 🍀 Nellziade ( View Tweet)
🔍 Do posterior element lesions progress over 10 years in axSpA?
Data from the DESIR inception cohort (n=320) says RARELY!
But baseline PE inflammation raises facet ankylosis risk ~70-fold
#POS0189 #EULAR2026 @RheumNow https://t.co/PdwlPGjKqK
Nelly ZIADE 🍀 Nellziade ( View Tweet)
🧪 Can genetics predict TNFi response in PsA?
OUTPASS GWAS (n=329): High BMI, comorbidities & novel XKR4 locus linked to non-response at 6 months
#POS0087 #EULAR2026 @rheumnow
Nelly ZIADE 🍀 Nellziade ( View Tweet)
From Skepticism to Reconsideration: 4‑Year CAR‑T Outcomes in Lupus
Chimeric antigen receptor (CAR) T‑cell therapy, long established in hematologic malignancies, is now emerging as a transformative approach in systemic lupus erythematosus (SLE), a disease historically managed https://t.co/Dmmw90XnuF
Dr. John Cush RheumNow ( View Tweet)
☂️What is an umbrella meta-analysis?
It's a meta-analysis of meta-analyses ☔️
⬇️This one showed the effect of diet supplementation on several RA outcomes
Unfortunately, most studies have low levels of evidence
#umbrella #rainy_London #EULAR2026 @rheumnow https://t.co/kYPchXEexn
Nelly ZIADE 🍀 Nellziade ( View Tweet)
🔬 Can baseline T cell phenotype predict PsA treatment response?
COLIPSO cohort (n=17): YES!
Higher Treg & activated CD4+ cells predict DAPSA & joint improvement
#POS0083 #EULAR2026 @RheumNow https://t.co/UIs6LXAWAY
Nelly ZIADE 🍀 Nellziade ( View Tweet)
🔍 Are 2025 ASAS-SPARTAN criteria valid in early axSpA?
SPACE cohort (n=669):
HIGH specificity (97.5%) but LOWER sensitivity (60%) vs 2009 criteria (83%)
#OP0239 #EULAR2026 @RheumNow https://t.co/9wNbtcbP0l
Nelly ZIADE 🍀 Nellziade ( View Tweet)
💉 Does ivarmacitinib (selective #JAK1i work in nr-axSpA?
Phase 3 RCT (n=304):
ASAS40 39.7% vs 24.8% placebo at week 12
with sustained benefit at week 24
#OP0237 #EULAR2026 @RheumNow https://t.co/kofXnPp6qQ
Nelly ZIADE 🍀 Nellziade ( View Tweet)
⚖️ Does BMI outrank treatment in early PsA outcomes?
YES - SPEED trial AI analysis:
BMI #1 predictor of PASDAS at 1yr in 192pts
#OP0187 #EULAR2026 @RheumNow https://t.co/9cZG7AWau2
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Good news! #Survival in #SLE is improving
#SLR of #lupus publications over time in 233 publications
Bad news - still a mortality gap!
#EULAR2026
@RheumNow @eular_org
ABST#POS0684 https://t.co/PVmQI2duYS
Janet Pope Janetbirdope ( View Tweet)
💉 Does bimekizumab work in real-world PsA?
YES - EuroSpA: 76% retention at 6months
46% DAPSA LDA in 787pts across 12 registries
#OP0185 #EULAR2026 @RheumNow https://t.co/TXS3r9mZXB
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Sustained remission in #SLE at 5 yrs w CAR-T
8 severe SLE patients treated with
autologous CD19-CAR T cells
(Zorpocel; Miltenyi Biomedicine)
#antiDNA and #SLEDAI #antiSm ➡️prolonged suppression
Big ? - how long will it work for
Impressive!
@RheumNow #EULAR2026
#EULARbest #729 https://t.co/8iOSImX3w6
Janet Pope Janetbirdope ( View Tweet)
🔎 Can US predict PsA progression from psoriasis?
YES: synovio-entheseal inflammation predicts progression in 183pts prospective cohort
#OP0183 #EULAR2026 @RheumNow https://t.co/7B9KU60qFd
Nelly ZIADE 🍀 Nellziade ( View Tweet)
🦴 What drives enthesophytes in PsA?
SITE-SPECIFIC:
Pelvic driven by disease activity+BMI
Calcaneal by BMI+damage
in a 1596pts cohort
OP0182 #EULAR2026 @RheumNow https://t.co/4RxgjJ2V9u
Nelly ZIADE 🍀 Nellziade ( View Tweet)
